Skip to contentE
Endonovo Therapeutics, Inc.
E
ENDVEndonovo Therapeutics, Inc. Q2 2022 · 10-Q
Revenue$650.00$650.00−97.9% vs Q2 2021 Net Income-$2.53M-$2.53MN/M vs Q2 2021 EPS Diluted-$0.02-$0.02N/M vs Q2 2021 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endonovo Therapeutics, Inc. · CIK 1528172 · Engraved from SEC EDGAR
Operating Cash Flowderived-$206,482N/M Margins · derivedGross margin41.1%−57.3 pt vs Q2 2021
Operating margin-276730.6%−274848.3 pt vs Q2 2021
Net margin-388635.5%−384353.8 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 22, 2022 · 53 d after period end